Journal Article10.1056/NEJM199007123230201
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Nelson B. Watts,S. T. Harris,Harry K. Genant,Richard D. Wasnich,Paul D. Miller,Rebecca D. Jackson,A.A. Licata,Philip D. Ross,G C Woodson rd,M. J. Yanover +9 more
TL;DR: A prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia to determine the effects of etidronate in the treatment of postmenopausal osteoporosis.
read more
Abstract: Background. To determine the effects of etidronate (a bisphosphonate that inhibits osteoclast-mediated bone resorption) in the treatment of postmenopausal osteoporosis, we conducted a prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia. Methods. The patients were randomly assigned to treatment with phosphate (1.0 g) or placebo twice daily on days 1 through 3, etidronate (400 mg) or placebo daily on days 4 through 17, and supplemental calcium (500 mg) daily on days 18 through 91 (group 1, placebo and placebo; group 2, phosphate and placebo; group 3, placebo and etidronate; and group 4, phosphate and etidronate). The treatment cycles were repeated eight times. The bone density of the spine was measured by dual-photon absorptiometry, and the rates of new vertebral fractures were determined from sequential radiographs. Results. After two years, the patients receiving etidro...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Robert M. Neer,Claude D. Arnaud,Jose R. Zanchetta,Richard L. Prince,Gregory A Gaich,Jean-Yves Reginster,Anthony B. Hodsman,Erik Fink Eriksen,Sophia Ish-Shalom,Harry K. Genant,Ouhong Wang,Bruce H. Mitlak +11 more
TL;DR: Treatment of postmenopausal osteoporosis with parathyroid hormone decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated.
4.6K
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
3.9K
Vertebral fracture assessment using a semiquantitative technique
TL;DR: The semiquantitative approach can be applied reliably in vertebral fracture assessment when performed using well‐defined criteria, and this approach was compared with a quantitative morpho‐metric approach.
3.5K
•Book
Users' Guides to the Medical Literature
Gordon H. Guyatt,Drummond Rennie +1 more
- 01 Jan 2001
TL;DR: Without a way of critically appraising the information they receive, clinicians are relatively helpless in deciding what new information to learn and decide how to modify their practice.
3.4K
Assessment of fracture risk and its application to screening for postmenopausal osteoporos
L. Alexeeva,P. Burkhardt,C. Christiansen,C. Cooper,P. Delmas,O. Johnell,C. Johnston,J. Kanis,P. Lips,Lee J. Melton,P. Meunier,Ego Seeman,J. Stepan,A. Tosteson,N. Khaltaev,J. P. Bonjour,H. Gong-Yi,R. Lindsay +17 more
- 01 Jan 1994
TL;DR: There is little evidence that osteoporosis can usefully be tackled by a public health policy to influence risk factors such as smoking, exercise and nutrition, so the selective use of screening techniques will improve the cost-benefit ratio of intervention.
3.2K
References
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
B. Lawrence Riggs,Stephen F. Hodgson,W. Michael O'Fallon,Edmund Y. S. Chao,Heinz W. Wahner,Joan M. Muhs,Sandra L. Cedel,L. Joseph Melon +7 more
TL;DR: It is concluded that fluoride therapy increases cancellous but decreases cortical bone mineral density and increases skeletal fragility, and the fluoride-calcium regimen was not effective treatment for postmenopausal osteoporosis.
1.1K
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
TL;DR: Etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures.
958
Quantitative computed tomography for prediction of vertebral fracture risk.
TL;DR: Vertebral compression fractures or wedging was generally absent in patients with vertebral mineral values above 110 mg cm-3, whereas almost all patients with values below 65 mgcm-3 had fractures.
410
Long-term calcitonin therapy in postmenopausal osteoporosis
Helen E. Gruber,Joel L. Ivey,David J. Baylink,Meredith Matthews,Wil B. Nelp,Karen Sisom,Charles H. Chesnut +6 more
TL;DR: Iliac crest bone biopsies showed a significantly greater percent total bone area in treated compared to control patients at 2 years, and a significantly decreased percent resorbing surface in treated patients when evaluated by paired difference from baseline.
332